{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:54:25Z","timestamp":1790844865002,"version":"4.1.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Prostate cancer risk is currently represented by two largely separate genomic layers. Germline polygenic scores estimate inherited susceptibility before diagnosis, whereas tumor genomic and transcriptomic classifiers estimate biological aggressiveness and treatment response after tissue acquisition. Artificial intelligence can connect these layers, but simply concatenating high-dimensional features is unlikely to produce transportable clinical tools. This Mini Review examines how biologically informed machine learning, single-cell and spatial atlases, whole-omics response models, and validated tissue classifiers are reshaping prostate cancer risk stratification. We argue that the most useful architecture is a stage-aware system: ancestry-calibrated germline risk first modifies screening intensity; tissue or liquid-biopsy models then resolve tumor state; and longitudinal molecular measurements update risk under treatment. Evidence is strongest for polygenic enrichment of screening populations and for locked transcriptomic classifiers tested in randomized-trial cohorts. By contrast, many multi-omics models remain retrospective, dataset-dependent, and weakly calibrated across ancestry, disease stage, and specimen type. Progress requires explicit clinical decision points, external and prospective validation, uncertainty reporting, ancestry-aware calibration, and comparisons against simpler clinicopathological models. A unified framework should therefore treat artificial intelligence not as a single prognostic score, but as an auditable sequence of genomic updates that links inherited susceptibility to evolving tumor biology.<\/jats:p>","DOI":"10.3389\/fgene.2026.1969511","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:54:40Z","timestamp":1790841280000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["From inherited susceptibility to tumor state: toward a stage-aware architecture for genomic risk stratification in prostate cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Ziheng","family":"Zheng","sequence":"first","affiliation":[{"name":"The First Clinical College of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuechun","family":"Yang","sequence":"additional","affiliation":[{"name":"The First Clinical College of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqian","family":"Ou","sequence":"additional","affiliation":[{"name":"The First Clinical College of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuedong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Tongliang Hospital of the First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyong","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Tongliang Hospital of the First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancers","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.euf.2022.06.009","article-title":"Prognostic role of rna expression molecular biomarkers in prostate and bladder cancers","volume":"8","author":"Ahmed","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"B3","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat. Genet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11912-024-01493-x","article-title":"Germline mutations and ancestry in prostate cancer","volume":"26","author":"Bataba","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11934-023-01193-2","article-title":"Assessment of prostate and bladder cancer genomic biomarkers using artificial intelligence: a systematic review","volume":"25","author":"Bazarkin","year":"2024","journal-title":"Curr. Urol. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e2305724","DOI":"10.1002\/advs.202305724","article-title":"Integration analysis of single-cell multi-omics reveals prostate cancer heterogeneity","volume":"11","author":"Bian","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/pros.24058","article-title":"Validation of a prostate cancer polygenic risk score","volume":"80","author":"Black","year":"2020","journal-title":"Prostate"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-14-2603","article-title":"Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer","volume":"21","author":"Blume-Jensen","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41391-023-00766-z","article-title":"Genomic classifiers and prognosis of localized prostate cancer: a systematic review","volume":"28","author":"Boyer","year":"2025","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e22394","DOI":"10.2196\/22394","article-title":"Radiomic and genomic machine learning method performance for prostate cancer diagnosis: systematic literature review","volume":"23","author":"Castaldo","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/bmj-2023-078378","article-title":"Tripod+ Ai statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"Bmj"},{"key":"B12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide Association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat. Genet."},{"key":"B13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an rna expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective Study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.ajhg.2023.05.010","article-title":"Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry","volume":"110","author":"Darst","year":"2023","journal-title":"Am. J. Hum. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1038\/s41467-023-37647-x","article-title":"Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning","volume":"14","author":"de Jong","year":"2023","journal-title":"Nat. Commun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1056\/NEJMc2507786","article-title":"Screening for prostate cancer with a polygenic risk score","volume":"393","author":"Eklund","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-021-03922-4","article-title":"Biologically informed deep neural network for prostate cancer discovery","volume":"598","author":"Elmarakeby","year":"2021","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"100247","DOI":"10.1016\/j.modpat.2023.100247","article-title":"Predicting prostate cancer molecular subtype with deep learning on histopathologic images","volume":"36","author":"Erak","year":"2023","journal-title":"Mod. Pathol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41746-022-00613-w","article-title":"Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials","volume":"5","author":"Esteva","year":"2022","journal-title":"NPJ Digit. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2300057","DOI":"10.1200\/cci.23.00057","article-title":"Multi-omic integration of blood-based tumor-associated genomic and lipidomic profiles using machine learning models in metastatic prostate cancer","volume":"7","author":"Fang","year":"2023","journal-title":"JCO Clin. Cancer Inf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s43018-024-00787-0","article-title":"Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer","volume":"5","author":"Fernandez-Mateos","year":"2024","journal-title":"Nat. Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1038\/s41467-024-45475-w","article-title":"Prediction of plasma ctdna fraction and prognostic implications of liquid biopsy in advanced prostate cancer","volume":"15","author":"Fonseca","year":"2024","journal-title":"Nat. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.annonc.2023.06.001","article-title":"Fragmentomic analysis of circulating tumor DNA-targeted cancer panels","volume":"34","author":"Helzer","year":"2023","journal-title":"Ann. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur. Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.eururo.2017.03.036","article-title":"Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathologic features","volume":"73","author":"Karnes","year":"2018","journal-title":"Eur. Urol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A 17-Gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur. Urol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41698-022-00266-8","article-title":"Prostate cancer polygenic risk score and prediction of lethal prostate cancer","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Invest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41416-024-02761-0","article-title":"An 18-Gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer: Genetics and genomics","volume":"131","author":"Lin","year":"2024","journal-title":"Br. J. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.1016\/S2589-7500(20)30218-1","article-title":"Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the Consort-Ai extension","volume":"2","author":"Liu","year":"2020","journal-title":"Lancet Digit. Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1056\/NEJMoa2407934","article-title":"Assessment of a polygenic risk score in screening for prostate cancer","volume":"392","author":"McHugh","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e082505","DOI":"10.1136\/bmj-2024-082505","article-title":"Probast+Ai: an updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods","volume":"388","author":"Moons","year":"2025","journal-title":"BMJ"},{"key":"B34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12916-016-0613-7","article-title":"Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics","volume":"14","author":"Moschini","year":"2016","journal-title":"BMC Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The molecular taxonomy of primary prostate cancer","volume":"163","year":"2015","journal-title":"Cell"},{"key":"B37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the nrg oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/biostatistics\/kxp009","article-title":"Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment psa: a joint modeling approach","volume":"10","author":"Proust-Lima","year":"2009","journal-title":"Biostatistics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-20-2371","article-title":"Characterizing Cdk12-Mutated prostate cancers","volume":"27","author":"Rescigno","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41585-022-00580-7","article-title":"Germline testing and genetic counselling in prostate cancer","volume":"19","author":"Russo","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e123468","DOI":"10.1172\/jci.insight.123468","article-title":"Transcriptomic heterogeneity in multifocal prostate cancer","volume":"3","author":"Salami","year":"2018","journal-title":"JCI Insight"},{"key":"B43","doi-asserted-by":"publisher","first-page":"j5757","DOI":"10.1136\/bmj.j5757","article-title":"Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts","volume":"360","author":"Seibert","year":"2018","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","first-page":"13901","DOI":"10.1038\/s41598-025-96683-3","article-title":"Multi-omics analysis constructs a novel neuroendocrine prostate cancer classifier and classification system","volume":"15","author":"Shen","year":"2025","journal-title":"Sci. Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ijrobp.2023.04.010","article-title":"Genomic classifier performance in intermediate-risk prostate cancer: results from nrg oncology\/rtog 0126 randomized phase 3 trial","volume":"117","author":"Spratt","year":"2023","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"B46","doi-asserted-by":"publisher","first-page":"140","DOI":"10.6004\/jnccn.2026.0023","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 5.2026","volume":"24","author":"Spratt","year":"2026","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B47","doi-asserted-by":"publisher","first-page":"218","DOI":"10.7326\/ANNALS-24-00700","article-title":"Impact of genomic classifiers on risk stratification and treatment intensity in patients with localized prostate cancer: a systematic review","volume":"178","author":"Tabriz","year":"2025","journal-title":"Ann. Intern Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"e2400145","DOI":"10.1200\/PO.24.00145","article-title":"Prostate cancer risk stratification in NRG oncology phase III randomized trials using multimodal deep learning with digital histopathology","volume":"8","author":"Tward","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","article-title":"Reporting and interpreting decision curve analysis: a guide for investigators","volume":"74","author":"Van Calster","year":"2018","journal-title":"Eur. Urol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41591-022-01772-9","article-title":"Reporting guideline for the early-stage clinical evaluation of decision support systems driven by artificial intelligence: decide-ai","volume":"28","author":"Vasey","year":"2022","journal-title":"Nat. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","article-title":"Genetics and biology of prostate cancer","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/cncr.34790","article-title":"A novel prostate cancer subtyping classifier based on luminal and basal phenotypes","volume":"129","author":"Weiner","year":"2023","journal-title":"Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.euo.2018.11.002","article-title":"Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer","volume":"2","author":"Xu","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in Asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat. Rev. Urol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1969511\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:54:41Z","timestamp":1790841281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1969511\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":54,"alternative-id":["10.3389\/fgene.2026.1969511"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1969511","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"1969511"}}